This week's episode covers new developments affecting the US healthcare market including expanded buprenorphine treatment via telemedicine, HHS renewal of the opioid crisis public health emergency, hemodialysis bloodlines added to the shortage list, Optum Rx's shift to cost-based reimbursement, Jefferson Health going out-of-network for Cigna commercial members, cost-effectiveness study of a heart failure management system, blockchain technology enhancing data integrity in FDA submissions, Health Care Service Corporation's $3.7 billion acquisition of Cigna's Medicare Advantage business, FCC Chair warning about merger blocks for companies with DEI policies, delayed telehealth buprenorphine prescribing rule, academic medical centers' concerns about NIH funding cuts, FDA approval of Arbli oral suspension for hypertension, Arizona's Differential Adjusted Payments notice, Governor Newsom's $2.8 billion request for Medi-Cal, CMS terminating four Medicare payment models early, and Aledade and Humana expanding their value-based partnership to rural sites. 

In this week's Market Access Insights, Sarah and Michael deliver comprehensive coverage of critical healthcare developments with significant stakeholder implications. The episode examines CMS's strategic repositioning through model terminations including Primary Care First, manufacturer participation in Medicare drug price negotiations, and MedPAC's divergent payment recommendations across care settings. Additional highlights include the $23.7 billion Walgreens acquisition, new drug approvals expanding treatment options, and extended telehealth flexibilities through September 2025. This episode provides essential context on how these policy changes and market developments affect providers, payers, and patients across the U.S. healthcare landscape.

## Key Topics
- CMS Innovation Center portfolio changes and model terminations
- Medicare drug price negotiation program's second cycle
- MedPAC payment recommendations for FY2026
- Proposed ACA Marketplace reforms affecting eligibility and enrollment
- Walgreens' $23.7 billion acquisition by Sycamore Partners
- Medicare Physician Fee cuts and telehealth flexibility extensions
- FDA approvals: Omlyclo for allergic conditions and Encelto gene therapy
- State-level initiatives: California's insulin cost-sharing cap and Florida's prescription drug disposal

## Relevant Stakeholder Impacts
- **Providers**: Transitions from terminated CMS models, physician fee cuts, noncompete agreement bans
- **Payers**: Medicare drug price negotiations, Medicare Advantage overpayment scrutiny
- **Patients**: Expanded access to non-opioid pain management, telehealth services, and fertility care
- **Manufacturers**: Drug price negotiation participation, FDA's increased use of real-world evidence

In this episode of Market Access Insights, hosts Sarah and Michael dive into the most significant healthcare developments for the week of March 3, 2025. Listeners will gain valuable insights into how recent policy changes and market developments affect providers, payers, and patients across the U.S. healthcare system.

**Episode Highlights:**

**CMS Updates**

- New clarifications on billing for mechanical ventilation and orphan drug reimbursement

- Corrections to outpatient coding for tissue markers to prevent payment denials

- Medicare Advantage and Part D changes, including premium increases

- Revised payer pricing strategies aimed at streamlining billing and reducing improper claims

**Federal Policy Changes**

- Executive order on healthcare price transparency (February 25, 2025)

- New requirements for hospitals to publish machine-readable pricing information

- Medicare telehealth policy refinements

- Extended timeline (180 days) for providers to address overpayment errors

**Market Access News**

- Enhanced value-based rewards in Medicare Advantage D-SNP plans

- Expanded chiropractic coverage in Medicaid

- Innovative partnership between athenahealth and Abridge

- Projected rising healthcare costs and potential loss of marketplace premium tax credits

**HEOR Developments**

- Increased integration of real-world evidence and AI in clinical decision-making

- Restructuring in biopharma HEOR groups

- Health equity improvements and federal funding concerns

- Impact of RWE on approval processes and value-based treatment decisions

**Healthcare Mergers & Acquisitions**

- Prime Healthcare's acquisition of eight Illinois hospitals

- Strategic merger between Azara Healthcare and i2i Population Health

- Potential Walgreens breakup proposal affecting retail pharmacy operations

- Private equity activity in healthcare restructuring

**Hospital Payment Policies**

- Enhanced price transparency enforcement with standardized templates

- Proposed reimbursement increases for outpatient departments

- New global budget models and digital transformation in Medicaid claim processing

- Legislative proposals affecting safety-net hospitals

**New Drug Approvals**

- Expanded use of buprenorphine extended-release injection for opioid disorder

- Fast Track designations for innovative cancer treatments

- Accelerated review for rare disease therapies

- First-in-class copper intrauterine device approval for non-hormonal birth control

**Reimbursement Policy Changes**

- Proposed adjustment to Medicare Physician Fee Schedule

- Potential 6.43 percent net reduction mitigation

- Expiring telehealth flexibilities (March 31 deadline)

- Revised UnitedHealthcare policies and MIPS threshold freezes

**Value-Based Contracting Trends**

- Hybrid payment models blending fee-for-service with outcome-based metrics

- Medicare Advantage star ratings tied to denial transparency

- Expanded primary care agreements

- New pilot programs for bundled payments and shared risk arrangements

Join Sarah and Michael each week for the latest insights on healthcare market access developments and their implications for the U.S. healthcare ecosystem.

*Market Access Insights is a weekly podcast providing comprehensive analysis of healthcare market access and policy developments.*